Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

MEMY

252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 | Laatste | Omlaag ↓
  1. [verwijderd] 21 mei 2008 16:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Laatste koers Verschil


    0.83 USD +0.17 (+25.76 %)
    Bid Ask
    0.80 0.84
    Bid hvh Ask hvh
    3400 3000
    Volume Tijdstip
    515969 2008-05-21 15:58:44
    Slotkoers Openingskoers
    0.66 0.71
    Laagste v/d dag Hoogste v/d dag
    0.69 0.84
    __________ Niet te bevatten meer,blijft gaan.
  8. [verwijderd] 21 mei 2008 17:44

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    GhosTWolF schreef:

    en weer terug.
    Ongelooflijk...klapte helemaal in elkaar net,zou er iets gruwelijks gelekt zijn ?,van +40 naar -40% net,waanzin dit,wilde op een haar na weer terug instappen op 0,70,ik kom goed weg.
  10. [verwijderd] 21 mei 2008 18:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    GhosTWolF schreef:

    en weer terug.
    ~~Day's Range: 0.4500 - 0.8898~~ scheelt maar 100%,hahaha,en dit zonder nieuws ? niet meer te volgen dit.
  12. [verwijderd] 26 november 2008 04:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Blijkbaar zit er hier niemand meer in op dit forum gezien de overname van het bedrijf gisteren meegedeeld voor $0.61 per aandeel.300% hoger op de slot koers van $0.15 op maandag.

    Last Trade: 0.6000
    Trade Time: 4:00PM ET
    Change: Up 0.4545 (312.37%)
    Prev Close: 0.15
    Open: 0.58
    Day's Range: 0.5600 - 0.6000
    52wk Range: 0.06 - 0.89
    Volume: 12,352,847

    Roche (RHHBY) (JOBS) Signs Definitive Agreement to Acquire Memory Pharmaceuticals (MEMY) for Approximately $50 Million
    11/25/2008

    NUTLEY, N.J. and MONTVALE, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Roche and Memory Pharmaceuticals (Nasdaq: MEMY - News) today announced that the two companies have signed a definitive merger agreement for Roche to acquire all the outstanding shares of Memory Pharmaceuticals in an all-cash transaction for an aggregate price of approximately USD 50 million.

    Memory Pharmaceuticals develops innovative drug candidates for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. Memory Pharmaceuticals' nicotinic alpha-7 agonist drug candidates in these disease areas are already in partnered programmes with Roche: R3487/MEM 3454 is in phase II clinical trials for Alzheimer's disease and schizophrenia; R4996/MEM 63908 is in phase I for Alzheimer's disease.

    "Acquiring Memory Pharmaceuticals will enable Roche to secure the future development of its promising nicotinic alpha-7 agonists," said William Burns, CEO Division Roche Pharmaceuticals. "The innovative work carried out by the scientists at Memory Pharmaceuticals will be fully integrated into Roche's R&D portfolio with the aim of providing new hope for patients and caregivers affected by devastating diseases such as Alzheimer's."

    Jonathan Fleming, Chairman of the Board of Directors of Memory Pharmaceuticals said: "Since founding Memory Pharmaceuticals in 1998, we have focused on developing medicines that could make a real difference to the lives of CNS patients. I am proud of the progress our dedicated team has made and I am confident that Roche's capabilities and experience in the CNS field will enable our research to realise its full potential."

    Terms of the agreement

    Under the terms of the merger agreement, Roche will commence a tender offer to acquire all of the outstanding shares of Memory common stock at a price of $0.61 per share in cash. This price represents a 319% premium to the closing price on 24 November 2008. The closing of the tender offer will be subject to the tender of a number of shares that, together with the shares owned by Roche, represent a majority of the total number of outstanding shares (assuming the exercise of all exercisable options and warrants having an exercise price per share less than or equal to the tender offer price) and other customary conditions. Following completion of the tender offer, Roche will acquire all remaining shares through a second step merger. Directors, officers and stockholders holding approximately 29.5% of the outstanding shares have agreed to tender their shares and otherwise support the transaction. Additional information regarding the transaction will be set out in the offer to purchase and other disclosure documents to be provided to stockholders in connection with the transaction.

    About Memory Pharmaceuticals

    Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit www.memorypharma.com.

    www.biospace.com/news_story.aspx?Stor...

252 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.108
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.120
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.849
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.823
Aedifica 3 926
Aegon 3.258 323.067
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.903
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.280
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.244
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.808
AMG 971 134.310
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.053
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.802
Arcelor Mittal 2.034 320.958
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.600
ASML 1.766 109.925
ASR Nederland 21 4.511
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.892
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449

Macro & Bedrijfsagenda

  1. 26 maart

    1. Economische groei Q4 2e raming (NL)
    2. Consumenten- en producentenprijzen februari (VK)
    3. Consumentenvertrouwen maart (Fra)
    4. Randstad - Jaarvergadering
    5. Hypotheekaanvragen - wekelijks (VS)
    6. Orders voor duurzame goederen februari (VS)
    7. Olievoorraden - wekelijks (VS)

  2. 27 maart

    1. Exor Q4-cijfers
    2. Sligro Q4-cijfers
    3. Hennes & Mauritz Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda